Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services (PPFP-IZ)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01115361|
Recruitment Status : Completed
First Posted : May 4, 2010
Last Update Posted : March 29, 2012
|Condition or disease||Intervention/treatment||Phase|
|Contraception||Behavioral: Family planning for postpartum women||Not Applicable|
To determine the effectiveness of an intervention, which is designed to increase contraceptive prevalence among postpartum women attending vaccination services who desire to either space or limit their pregnancies, thus reducing unmet contraceptive need in this population.
A. Brief, concise messages conveyed to women during group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.
B.IEC materials such as posters and brochures that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.
C.Use of a screening tool (Appendix A) to assess pregnancy risk for postpartum women coupled with a brief counseling message depending upon risk classification which includes referral to FP services for those currently or soon-to-be at-risk of pregnancy.
D.Convenient offer of FP services to women attending vaccination services for their infants either concurrently with vaccination services, or at the same facility and on the same day, but at a different time from vaccination services.
Experimental, two-group (intervention/control) pretest (pre-intervention) /posttest (post-intervention) design 12 month intervention period. A mid-course collection of process data will also be conducted at 6 months to assess the degree to which the intervention is being implemented as intended and to provide an opportunity for corrective action if needed.
Participants: Women attending vaccination services for their infants, and vaccination and FP providers
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||800 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Improving Access to and Uptake of Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||October 2011|
|Actual Study Completion Date :||December 2011|
Experimental: PPFP in child immunization
Women attending immunization services for their infant will receive educational brochures, group education and individual counseling on the benefits of the health timing and spacing of births,, pregnancy risk and return to fertility during the extended postpartum period (12 months), and referral to family planning services for those who are interested.
Behavioral: Family planning for postpartum women
A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.
B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.
C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.
D.Convenient offer of FP services to women attending vaccination services for their infants.
No Intervention: Control - Standard of care
The control arm will receive standard of care infant immunization services.
- Use of a modern contraceptive method among postpartum women [ Time Frame: 1 year ]The outcome variable is a dichotomous variable - use of modern FP method: yes/no
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01115361
|Rwanda health care facilities|
|Principal Investigator:||Lisa S Dulli, PhD, MHS||FHI 360|
|Study Director:||Steve Sortijas, MPH||FHI 360|
|Principal Investigator:||Fidèle Ngabo, MD, MPH||Rwanda Ministry of Health|